Circulating YKL‐40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. (25th April 2014)

• Record Type: Journal Article
• Authors: Bjørn, Mads Emil; Andersen, Christen Lykkegaard; Jensen, Morten Krogh; Hasselbalch, Hans C.
• Is Part Of: European journal of haematology. Volume 93:Number 3(2014:Sep.)
• Page Start: 224
• Page End: 228
• Publication Date: 2014-04-25
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12332
• Languages: English
• ISSNs: 0902-4441

Abstract

<abstract abstract-type="main" id="ejh12332-abs-0001"> <title>Abstract</title> <p>Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL‐40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL‐40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL‐40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL‐40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL‐40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, <italic> P</italic> = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.</p> </abstract>